Evidence map›Paper›PMID 39979838›Full record

ArticleBMC cancer2025

Up-regulation of m

Lulu Li, Rong Zhang, Yongsheng Li

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Crosstalk between mFrontiers in immunology · 2026
    Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lulu LiDepartment of Medical Oncology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, 046000, China.
Rong ZhangDepartment of Medical Oncology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, 046000, China.
Yongsheng LiDepartment of Colorectal Surgery, Heping Hospital Affiliated to Changzhi Medical College, No.110, Yan'an South Road, Changzhi, Shanxi Province, 046000, China. jzcwk@czmc.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is a common malignant tumor. N

methodsThe role of METTL14, an m

resultsOur data suggested that METTL14 was up-regulated in CRC cell lines, and over-expression of METTL14 suppressed cell proliferation and glycolysis. Meanwhile, ATF2 m

conclusionIntervention with METTL14 mediated m

Indexed as

CarcinogenesisColorectal NeoplasmsGlycolysisMethyltransferasesAdenosineAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMiceMice, Inbred BALB CMice, NudeUp-RegulationXenograft Model Antitumor AssaysAdenosineMethyltransferasesMETTL14 protein, humanN-methyladenosineATF2Glycolysism6AMETTL14Volorectal cancer

Identifiers

PMID39979838
PMCPMC11844156

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.